13 research outputs found
Swift Cure of a Chronic Wound Infected With Multiresistant Staphylococcus aureus in an Elderly Patient With Stage 5 Renal Disease
We present a case of a 91-year-old female with stage 5 renal disease,
diabetes type 2, and considerable weakness, suffering from a 2-month-old
wound infected by a multiresistant Staphylococcus aureus. The wound
measured 7 cm in length, 5 cm in width, and 1.5 cm in depth, having
purulent white edges and exudates exceeding the size of the wound. The
systemic antibiotic use was opposing to improve the patient’s clinical
condition due to underlying nephrotoxicity that may have deteriorated
renal failure and resistance of the infecting pathogen. The halogenated
taurine (Tau) derivatives N-chlorotaurine (NCT) and N-bromotaurine
(NBrT) with potent anti-inflammatory and antimicrobial efficacy were
alternatively employed as combination topical treatment to provide a
therapeutic solution. Each agent was applied separately with an interval
of 5 minutes as a 1% spray in aqueous solution every 30 minutes during
the day for 3 days. This treatment was very well tolerated and led to
rapid disappearance of the purulent exudate, rapid epithelialization,
and complete healing. To avoid relapse, the application was continued 4
times daily for a further 4 days. No complications occurred in the
course of treatment. This case report confirms the therapeutic efficacy
of NCT in chronic purulent wounds. NBrT is well tolerated, too, and can
be used in combination with NCT in emergency clinical settings. Its
potential as a single agent should be investigated in further studies.
Advancement of wound closure by these agents proved to be life-saving
for this patient. Further molecular research is needed to identify
mechanisms that promote wound healing
Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues
As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group